Chlamydia LPS antibody | CF 6J12
LPS is a common feature of the outer envelope of gram negative bacteria, which acts as a potent endotoxin, triggering an innate immune response. Studies have shown however, that whilst the LPS of Chlamydia trachomatis does evoke an immune response, it displays only weak endotoxic activity when compared to that of other bacteria such as Salmonella minnesota or Neisseria gonorrhoeae.
- Target Species
- Species Cross-Reactivity
Target Species Cross Reactivity Chlamydophila sp.
- N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline.
- Preservative Stabilisers
- <0.1% Sodium Azide (NaN3)
- Elementary bodies from C. trachomatis strain SAF2.
- Approx. Protein Concentrations
- IgG concentration 1.0mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the NS0/U mouse myeloma cell line.
- This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
- 12 months from date of despatch
- For research purposes only
Applications of Chlamydia LPS antibody
|Application Name||Verified||Min Dilution||Max Dilution|
Secondary Antibodies Available
Product Specific References
References for Chlamydia LPS antibody
Thornley, M.J. et al. (1985) Properties of monoclonal antibodies to the genus-specific antigen of Chlamydia and their use for antigen detection by reverse passive haemagglutination.
J Gen Microbiol. 131 (1): 7-15.
Xia M et al. (2013) Immunization of Chlamydia pneumoniae (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development.
PLoS One. 8 (12): e81056.
Campbell, S. et al. (1994) Lipopolysaccharide in cells infected by Chlamydia trachomatis.
Xia, M. et al. (2013) Immunization of Chlamydia pneumoniae. (Cpn)-infected Apob(tm2Sgy)Ldlr(tm1Her)/J mice with a combined peptide of Cpn significantly reduces atherosclerotic lesion development.
PLoS One. 8 (12): e81056.
Borth, N. et al. (2011) Functional interaction between type III-secreted protein IncA of Chlamydophila psittaci. and human G3BP1.
PLoS One. 6 (1): e16692.
Dlugosz, A. et al. (2010) Chlamydia trachomatis. antigens in enteroendocrine cells and macrophages of the small bowel in patients with severe irritable bowel syndrome.
BMC Gastroenterol. 10: 19.
Lantos, I. et al. (2018) Chlamydia pneumoniae Infection Exacerbates Atherosclerosis in ApoB100only/LDLR-/- Mouse Strain.
Biomed Res Int. 2018: 8325915.
Mosolygó, T. et al. (2019) Selenocompounds as Novel Antibacterial Agents and Bacterial Efflux Pump Inhibitors.
Ingalls, R.R. et al. (1995) The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated.
Infect Immun. 63 (8): 3125-30.
Fluorescent SpectraviewerWatch the Tool Tutorial Video ▸
How to Use the SpectraviewerWatch the Tool Tutorial Video ▸
- Start by selecting the application you are interested in, with the option to select an instrument from the drop down menu or create a customized instrument
- Select the fluorophores or fluorescent proteins you want to include in your panel to check compatibility
- Select the lasers and filters you wish to include
- Select combined or multi-laser view to visualize the spectra